Ptct stock company

Earnings Whisper Number for PTCT: Ptc Therapeutics Oct 29, 2019 · Ptc Therapeutics (PTCT) reports earnings on 6/1/2020. Shares are down 19.0% since reporting last quarter. The Earnings Whisper Score gives the statistical odds for the stock …

PTCT - PTC Therapeutics Inc. • BioPharmCatalyst NewsSee all news. 16 March 2020 PTC Therapeutics Announces Management Change. SOUTH PLAINFIELD, N.J., March 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that Marcio Souza, Chief Operating Officer, has resigned and will be leaving the company … PTCT - Stock quote for PTC THERAPEUTICS, INC. - MSN Money View the latest PTCT stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of PTC THERAPEUTICS, INC.. PTCT Price Target and Analyst Ratings (PTC Therapeutics) Oct 30, 2019 · 10 Wall Street analysts have issued ratings and price targets for PTC Therapeutics in the last 12 months. Their average twelve-month price target is $62.13, suggesting that the stock has a possible upside of 45.97%. The high price target for PTCT …

PTCT PTC Therapeutics, Inc. — Stock Price and Discussion ...

PTC Therapeutics, Inc. (PTCT) Stock Analysis & News ... Get breaking news and analysis on PTC Therapeutics, Inc. (PTCT) stock, price quote and chart, trading and investing tools. PTCT PTC Therapeutics, Inc. — Stock Price and Discussion ... Real-time trade and investing ideas on PTC Therapeutics, Inc. PTCT from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. PTC Therapeutics, Inc. (PTCT) Latest Stock News ...

PTCT: Get the latest PTC Therapeutics stock price and detailed information including PTCT news, historical charts and realtime prices.

PTCT Stock Quote - PTC Therapeutics, Inc. Stock Price Today PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. Analysts Have Mixed Ratings On PTC Therapeutics Inc ... Mar 12, 2020 · RBC Capital Mkts wasn’t the only research firm that published a report of PTC Therapeutics Inc., with other equities research analysts also giving their opinion on the stock. Citigroup advised investors in its research note published on February 20, 2020, to Neutral the PTCT stock while also putting a $71 price target. The Growth and Earning Thesis of PTC Therapeutics Inc ... PTC Therapeutics Inc. (NASDAQ:PTCT) stock is up 0.16% to close at $54.93 on Monday, 03/02/20. PTCT stock is higher by $0.09 from the previous closing price of $54.84 on volume of 1656168 shares. In the meantime, PTCT was trading in the Healthcare sector, the stock is trading -8.28% low as compared to its 52-week high price and 74.44% high as compared to its 52-week low price. Earnings Whisper Number for PTCT: Ptc Therapeutics

PTCT | PTC Therapeutics Inc. Stock Price & News - WSJ

PTCT - Ptc Therapeutics News - Barchart.com PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 6, 2020 it approved non-statutory stock options to purchase an aggregate of 103,750 shares of its common stock … Healthcare stock under pressure: PTC Therapeutics, Inc ... Mar 03, 2020 · PTC Therapeutics, Inc. (NASDAQ: PTCT) stock lost over 0.2% on March 3 rd, 2020 (as of 10:36 am GMT-5; Source: Google finance) after the company … PTCT Stock Quote - PTC Therapeutics, Inc. Stock Price Today PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. Analysts Have Mixed Ratings On PTC Therapeutics Inc ...

Information on stock, financials, earnings, subsidiaries, investors, and executives for PTC Therapeutics. Use the PitchBook Platform to explore the full profile.

The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings. Price Target Upside/Downside. According to  The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product  Company Rating. What our community thinks about PTC Therapeutics. CAPS Rating 2 out of 5. 26 Outperform. 15 Underperform. CAPS All Stars. 7 Outperform. View the latest PTC Therapeutics Inc. (PTCT) stock price, news, historical charts, and Full Year 2019 Financial Results and Provides a Corporate Update. Public · Traded as · NASDAQ: PTCT · Russell 2000 Component. Industry, Pharmaceuticals. Headquarters. South Plainfield, New Jersey. ,. United States. Website, ptcbio.com. PTC Therapeutics is a US pharmaceutical company focused on the development of orally 

Therapeutics (NasdaqGS:PTCT) - Share price, News ... PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. PTCT - PTC Therapeutics Inc. • BioPharmCatalyst NewsSee all news. 16 March 2020 PTC Therapeutics Announces Management Change. SOUTH PLAINFIELD, N.J., March 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that Marcio Souza, Chief Operating Officer, has resigned and will be leaving the company … PTCT - Stock quote for PTC THERAPEUTICS, INC. - MSN Money